Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 08, 2023

BUY
$9.99 - $18.71 $17,342 - $32,480
1,736 Added 46.0%
5,510 $102,000
Q2 2023

Aug 11, 2023

BUY
$9.17 - $19.29 $3,071 - $6,462
335 Added 9.74%
3,774 $41,000
Q1 2023

May 02, 2023

SELL
$12.53 - $21.71 $6,415 - $11,115
-512 Reduced 12.96%
3,439 $46,000
Q3 2022

Nov 09, 2022

BUY
$12.21 - $19.7 $732 - $1,182
60 Added 1.54%
3,951 $55,000
Q2 2022

Aug 15, 2022

SELL
$11.23 - $19.59 $2,100 - $3,663
-187 Reduced 4.59%
3,891 $54,000
Q1 2022

Jun 30, 2022

BUY
$13.37 - $17.79 $54,522 - $72,547
4,078 New
4,078 $66,000
Q2 2020

Aug 10, 2020

SELL
$46.7 - $92.04 $210,710 - $415,284
-4,512 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$48.35 - $118.68 $9,138 - $22,430
-189 Reduced 4.02%
4,512 $284,000
Q4 2019

Feb 13, 2020

BUY
$57.36 - $124.1 $18,297 - $39,587
319 Added 7.28%
4,701 $583,000
Q3 2019

Nov 13, 2019

SELL
$58.69 - $80.46 $3,697 - $5,068
-63 Reduced 1.42%
4,382 $291,000
Q2 2019

Aug 14, 2019

BUY
$77.77 - $120.68 $86,869 - $134,799
1,117 Added 33.56%
4,445 $354,000
Q1 2019

May 15, 2019

BUY
$91.83 - $120.68 $12,121 - $15,929
132 Added 4.13%
3,328 $372,000
Q4 2018

Feb 15, 2019

BUY
$85.79 - $126.46 $274,184 - $404,166
3,196 New
3,196 $322,000
Q3 2018

Nov 14, 2018

SELL
$88.49 - $127.55 $295,291 - $425,634
-3,337 Closed
0 $0
Q2 2018

Jul 18, 2018

SELL
$60.0 - $85.67 $29,640 - $42,320
-494 Reduced 12.89%
3,337 $280,000
Q1 2018

May 22, 2018

BUY
$52.72 - $67.25 $13,021 - $16,610
247 Added 6.89%
3,831 $236,000
Q4 2017

Feb 13, 2018

BUY
$58.2 - $72.76 $208,588 - $260,771
3,584
3,584 $209,000

Others Institutions Holding ICPT

About INTERCEPT PHARMACEUTICALS, INC.


  • Ticker ICPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,127,400
  • Description
  • Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...
More about ICPT
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.